Cell Therapy Oligonucleotides

Over the past 30 years, oligonucleotide research has become increasingly important as an avenue for new and innovative therapeutics. By 2024 global nucleic acid therapeutics market is projected to reach $ 7.23 B. Jodas is committed to explore the current landscape of oligonucleotide research for the development of oligonucleotide therapeutics to treat rare and orphan diseases.

Cell therapy oligonucleotides are highly target specific. By targeting the source of the pathogenesis, Oligo-mediated therapies have a higher chance of success than therapies targeting downstream pathway. They provide opportunity for addressing previously inaccessible drug targets especially in case of certain neurological disorders.

The promise of oligonucleotides making a difference to an increasing number of patients is driving Jodas  Expoim’s rapid implementation of research and manufacturing capabilities for oligonucleotide based drugs.

Jodas has know-how knowledge and capabilities in solid-phase synthesis, protecting group chemistry, purification by chromatography, ultra/diafiltration techniques, precipitation and lyophilization which are quintessential to develop and manufacture oligonucleotide therapeutics.

Porduct Portfolio and Pipeline (Cell Therapy Oligonucleotides):

The product portfolio and pipeline of synthetic Oligos at various stages of development comprises, APIs and formulations for spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD).